Tfh Cells
Tfh Cells - Related Videos
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
0 Views •
Cited by 38 •
2015
The transfer of bm12 lymphocytes into a C57BL/6 recipient is an established model of systemic lupus erythematosus. Here we describe how to initiate disease using this model and how to characterize T follicular helper cells, germinal center B cells and plasma cells by flow cytometry.
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
0 Views •
2025
This protocol describes the in vivo reprogramming of mouse cancer cells into type 1 dendritic-like cells within the tumor microenvironment through enforced expression of the transcription factors PU.1, IRF8, and BATF3.
22:06
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
0 Views •
Cited by 7 •
2007
This protocol details the derivation of transplantable hematopoietic stem cells from mouse embryonic stem cells (ESC) and their subsequent injection into lethally irradiated recipient mice. Briefly, ESC are differentiated as embryoid bodies, which are then infected with retroviral HoxB4 and co-cultured with OP9 stromal cells and hematopoietic cytokines.
02:47
Human ES cells: Starting Culture from Frozen Cells
0 Views •
2006
Here we demonstrate how our lab begins a HuES human embryonic stem cell line culture from a frozen stock.
10:54
Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations
0 Views •
Cited by 2 •
2012
Metaphase to anaphase transition is triggered through anaphase-promoting complex (APC/C)-dependent ubiquitination and subsequent destruction of cyclin B. Here, we established a system which, following pulse-chase labeling, allows monitoring cyclin B proteolysis in entire cell populations and facilitates the detection of interference by the mitotic checkpoint.
FAQs
CXCR5 directs these cells toward B-cell follicles by responding to the follicular chemokine environment, while Bcl-6 maintains the gene-regulatory program associated with follicular helper activity. Together, these features position Tfh cells where B-cell interactions occur and help preserve their specialized state. In cancer research, this organization is relevant because similar follicular programs can develop within tumors or tertiary lymphoid structures.
ICOS provides a contact-dependent signal between Tfh cells and B cells, whereas IL-21 supplies a cytokine-mediated signal. Their complementary roles allow cellular contact and soluble communication to work together during B-cell maturation and antibody production. Examining both pathways helps researchers assess how Tfh cells may influence the strength and character of antibody-related immune responses in cancer.
Tfh cells located in B-cell follicles or tertiary lymphoid structures are positioned within organized immune-cell environments that support interactions with B cells. Their location may therefore influence antibody responses and the broader arrangement of immune cells around a tumor. This spatial context matters because the same cell type can be interpreted differently depending on whether it appears within a structured immune region or another tumor-associated site.
Cancer studies examine Tfh cells within tumors and within tertiary lymphoid structures, which are organized immune-cell arrangements associated with tumor sites. These settings provide context for evaluating follicular activity, B-cell interactions, and potential antitumor antibody responses. Comparing these locations can help researchers relate Tfh-cell presence to immune organization rather than treating cell counts as isolated measurements.
The presence or activity of Tfh cells may be evaluated as an indicator of treatment response because these cells participate in B-cell maturation, antibody production, and immune organization within tumors or tertiary lymphoid structures. Their association with these processes can provide context for interpreting how tumor immunity changes during treatment. The overview supports their use as indicators, but not a universal response pattern.
Tfh cells influence several immune processes relevant to tumors, including B-cell maturation, antibody responses, and organization within tertiary lymphoid structures. Modulating their activity could therefore affect how immune cells coordinate against cancer. Their potential as immunotherapeutic targets follows from this regulatory position, although the appropriate strategy depends on how Tfh-cell activity relates to antitumor immunity in a particular tumor setting.